Work

Cost-Effectiveness of Epcoritamab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Year: 2023

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2023-181177

Authors: Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony Wang

Institutions: Genmab (United States), AbbVie (United States)

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389229018

Cites:

Cited by: 2

Related to: 10